
Show Notes
The 2025 San Antonio Breast Cancer Symposium featured four days filled with new research findings, poster presentations, and educational sessions. Marisa Weiss, MD, founder and chief medical officer of Breastcancer.org, offers her take on the top results.
Listen to the episode to hear Dr. Weiss explain:
how giredestrant, a new oral SERD for early-stage, hormone receptor-positive breast cancer, may change practice
a new use for Tukysa (chemical name: tucatinib) in metastatic HER2-positive disease
the lifestyle factors that can affect breast cancer risk and steps people can take to keep their risk as low as possible
More from Breastcancer.org Podcast
Actress Miranda McKeon was diagnosed with stage III breast cancer at age 19, just as she was starting her sophomore year of college. She talks about her experiences with diagnosis and treatment, as well as how she balanced presenting herself to her peers in a way that felt authentic when she was living an experience that was completely foreign to her.
Julia Maués didn’t decide to become an advocate, but her passion for patients learning science and scientists learning patient experiences propelled her to talk about her experiences.
Eleonora Teplinsky’s oncology practice has focused on people with breast cancer for more than a decade. Her new book, Beyond the Pink: Navigating Life, Health, and Breast Cancer, explains breast cancer risks, screening, diagnosis, and treatment, as well as topics that may not be discussed by all doctors.
Dr. Luba Perry is the founder and CEO of ReConstruct Bio, where she’s working to develop bioengineered living tissue implants made from a person’s own cells that then integrate with the body as living tissue. The first goal is to develop natural implants for breast reconstruction.
An advocate and communications expert with more than 20 years experience in international corporate marketing, Christina Wilhelm wrote It’s Breast Cancer, Now What? as a manual to help people navigate breast cancer treatment, return-to-work, and long-term follow-up care decisions.